CompletedNot Applicable

MMP-9, TIMP-9 in Lung Imaging and Functional of COVID-19

Indonesia78 participantsStarted 2021-03-15

Plain-language summary

This study aims to determine the role of the extracellular matrix in lung abnormalities in COVID-19 patients. Anatomical abnormalities of the lungs can be observed by the presence of abnormalities on a chest x-ray that is scored using the Brixia index. The presence of COVID-19 pneumonia can impact oxygenation disorders. It is hoped that knowing the relationship between biomarkers that affect the extracellular matrix and anatomical and functional abnormalities can open up new insights into new therapeutic opportunities. The balance of MMP-9 and TIMP-1 has been studied in relation to several lung diseases other than COVID-19.

Who can participate

Age range21 Years – 70 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * The patient is infected with COVID-19 with positive RT-PCR Swab results * Age 21-70 years * Men or Women * Various degrees of severity (mild, moderate, severe, critical) and comorbidities * the Chest X-ray was done * Willing to participate in research (signing informed consent) Exclusion Criteria: * The patient is TB active or has been treated for pulmonary TB * Patients with a history of ILD clinically * Patients with a history of asthma or COPD * Pregnant women * HIV/AIDS patients

What they're measuring

Anatomical abnormalities of the lungs.

Timeframe: Chest X-Ray checked 2-4 hours during admission in emergency room.

Functional abnormalities of the lungs.

Timeframe: Oxygen use and blood gas analysis checked 1-2 hours during admission in emergency room.

Trial details

NCT IDNCT05844215

SponsorUniversitas Airlangga

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2021-12-24

View on ClinicalTrials.gov More Pulmonary Infection trials